Actively Recruiting
The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients
Led by Cairo University · Updated on 2024-10-09
128
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial aims to evaluate the effect of dexmedetomidine in Sepsis-Associated Acute Kidney Injury in critically ill patients by answering the following questions: 1. What is dexmedetomidine's effect on kidney functions? 2. What is the safety and efficacy of dexmedetomidine in Sepsis-Associated Acute Kidney Injury? The investigator will compare dexmedetomidine to the standard sedative. The Participant will take either dexmedetomidine or the standard sedative during their hospitalization, with follow-up of the following: 1. Vital signs including blood pressure, body temperature, respiratory rate, heart rate, and oxygen saturation. 2. Laboratory data including kidney function tests, electrolytes, complete blood count, and liver function tests. 3. An electrocardiogram will be followed to check the heart's electrical activity. 4. The level of alertness or agitation to avoid over and under-sedation. 5. The level of organ dysfunction and mortality risks. 6. Duration of mechanical ventilation. 7. Duration of hospitalization.
CONDITIONS
Official Title
The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 21 years old
- Patients with sepsis who develop acute kidney injury within 48 hours during ICU stay
- Need for sedation due to mechanical ventilation (invasive or non-invasive) within 48 hours of acute kidney injury
You will not qualify if you...
- Severe bradycardia (heart rate less than 50 beats per minute), sick sinus syndrome, or second-to-third degree atrioventricular block unless a pacemaker is present
- Acute myocardial ischemia
- Mean arterial blood pressure less than 50 mmHg despite adequate resuscitation and vasopressor therapy at enrollment
- Pregnancy or lactation
- Duration of dexmedetomidine infusion less than 24 hours
- Severe valvular heart disease
- Active seizures during ICU admission requiring benzodiazepines
- Proven or suspected traumatic brain injury, intracranial hemorrhage, stroke, or spinal cord injury
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cairo University
Cairo, Egypt
Actively Recruiting
Research Team
K
Kanzy Hassan, B. Pharm
CONTACT
N
Nirmeen A Sabry, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here